{"id":36275,"date":"2026-10-16T17:41:00","date_gmt":"2026-10-16T12:11:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=36275"},"modified":"2026-10-12T15:42:07","modified_gmt":"2026-10-12T10:12:07","slug":"sirna-vs-antisense-oligonucleotides","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides","title":{"rendered":"siRNA vs. Antisense Oligonucleotides: Which RNA Technology Has Greater Commercial Potential?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6ad26136a0033\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6ad26136a0033\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides\/#siRNA_vs_ASO_Same_Goal_Very_Different_Machinery\" >siRNA vs. ASO: Same Goal, Very Different Machinery<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides\/#How_siRNA_Works_The_Catalytic_Silencer\" >How siRNA Works: The Catalytic Silencer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides\/#How_Antisense_Oligonucleotides_Work_The_Versatile_Modulator\" >How Antisense Oligonucleotides Work: The Versatile Modulator<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides\/#The_Commercial_Translation\" >The Commercial Translation<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides\/#The_Commercial_Scorecard_What_the_Approved_Drugs_Tell_Us\" >The Commercial Scorecard: What the Approved Drugs Tell Us<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides\/#siRNA_A_Blockbuster_Pipeline_in_the_Making\" >siRNA: A Blockbuster Pipeline in the Making<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides\/#Antisense_The_Pioneer_With_a_Strong_Second_Act\" >Antisense: The Pioneer With a Strong Second Act<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides\/#The_RNA_Drug_Pipeline_in_2026_Blockbuster_Potential_and_Clinical_Setbacks\" >The RNA Drug Pipeline in 2026: Blockbuster Potential and Clinical Setbacks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides\/#Emerging_siRNA_Drugs_The_Next_Wave_Aims_at_Mass_Markets\" >Emerging siRNA Drugs: The Next Wave Aims at Mass Markets<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides\/#Emerging_Antisense_Drugs_Big_Wins_and_Big_Setbacks_in_2026\" >Emerging Antisense Drugs: Big Wins and Big Setbacks in 2026<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides\/#The_Commercial_Verdict_Who_Has_the_Greater_Potential\" >The Commercial Verdict: Who Has the Greater Potential?<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>siRNA and ASOs are emerging as major RNA-based therapeutic platforms, enabling targeted disease treatment by silencing or modulating gene expression.<\/em><\/li>\n\n\n\n<li><em>siRNA holds a commercial advantage in revenue generation and dosing convenience. Marketed siRNA drugs generated approximately $4.2 billion in disclosed global net sales in 2025, driven by AMVUTTRA and LEQVIO.<\/em><\/li>\n\n\n\n<li><em>ASOs retain a strong commercial presence, particularly in neurology and rare genetic diseases. Approved therapies such as SPINRAZA and Sarepta&#8217;s exon-skipping drugs have established durable revenue streams.<\/em><\/li>\n\n\n\n<li><em>siRNA&#8217;s late-stage pipeline offers substantial growth potential, but important clinical risks remain. Zilebesiran, nucresiran, and plozasiran are advancing toward larger patient populations.<\/em><\/li>\n\n\n\n<li><em>Clinical setbacks have increased uncertainty for some ASO programs. The failure of pelacarsen to reduce cardiovascular events despite lowering lipoprotein(a), together with the lack of significant overall benefit in the WAINUA ATTR-CM trial, has challenged expectations for antisense therapies in cardiovascular disease.<\/em><\/li>\n<\/ul>\n\n\n\n<p>A little over a decade ago, silencing a disease gene with a few injections a year sounded like science fiction. Today it is a multi-billion-dollar business. Oligonucleotide drugs now sit among the fastest-growing classes in pharma, and two technologies lead the field: small interfering RNA (siRNA) and antisense oligonucleotides (ASOs). Both switch off disease at the RNA level. Both have produced blockbuster-scale products. But they are not interchangeable, and 2026 has been a year of sharp, sometimes surprising, readouts that changed the commercial picture for each of them.<\/p>\n\n\n\n<p>For anyone tracking the <a href=\"https:\/\/www.delveinsight.com\/report-store\/antisense-therapies-market-forecast\">antisense oligonucleotides market<\/a> and the wider siRNA therapeutics landscape, the stakes are unusually high right now. Capital is flowing toward every siRNA company with a late-stage asset, large pharmaceutical groups are signing partnerships for both modalities, and a wave of antisense oligonucleotides clinical trials has just reported mixed results. Knowing where each technology is strongest has become essential for investors, business development teams, and competitive-intelligence professionals deciding where to place their bets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sirna-vs-aso-same-goal-very-different-machinery\"><span class=\"ez-toc-section\" id=\"siRNA_vs_ASO_Same_Goal_Very_Different_Machinery\"><\/span><strong>siRNA vs. ASO: Same Goal, Very Different Machinery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Although both classes are built from short strands of nucleic acid, they are designed, delivered, and dosed in very different ways, and those differences shape every commercial decision that follows. siRNA technology harnesses a natural cellular defense called <a href=\"https:\/\/www.delveinsight.com\/blog\/emerging-rna-interference-drugs\">RNA interference<\/a>, while antisense drugs rely on a single strand that binds target RNA directly and can be chemically tuned to do several different jobs. Over the past decade, advances in chemical stabilization and liver-targeted delivery turned both approaches from laboratory curiosities into the foundation of modern siRNA medicines and antisense therapies. The sections below explain how each mechanism works and why those mechanisms translate into different strengths in the clinic and in the market.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-how-sirna-works-the-catalytic-silencer\"><span class=\"ez-toc-section\" id=\"How_siRNA_Works_The_Catalytic_Silencer\"><\/span><strong>How siRNA Works: The Catalytic Silencer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>siRNAs are short, double-stranded RNA molecules. Once inside a cell, they are loaded into the RNA-induced silencing complex (RISC), which uses the siRNA as a guide to find and cut matching messenger RNA (mRNA) in the cytoplasm. RISC is reusable, so a single siRNA can destroy many mRNA copies over a long period. That durability is why a modern siRNA therapy can be dosed as rarely as twice a year.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-how-antisense-oligonucleotides-work-the-versatile-modulator\"><span class=\"ez-toc-section\" id=\"How_Antisense_Oligonucleotides_Work_The_Versatile_Modulator\"><\/span><strong>How Antisense Oligonucleotides Work: The Versatile Modulator<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>ASOs are short, single-stranded molecules that bind target RNA through base pairing. Their strength is versatility. Depending on the chemical design, an ASO can:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Degrade RNA by recruiting the enzyme RNase H1<\/li>\n\n\n\n<li>Correct splicing to restore a missing protein or skip a faulty exon, as in spinal muscular atrophy and Duchenne muscular dystrophy<\/li>\n\n\n\n<li>Block translation by physically obstructing the ribosome<\/li>\n<\/ul>\n\n\n\n<p>ASOs also work in the nucleus, and they have a long track record in the central nervous system, where they are injected directly into the spinal fluid. That flexibility is why approved antisense oligonucleotides span such different diseases, from neuromuscular disorders to metabolic and rare genetic conditions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-the-commercial-translation\"><span class=\"ez-toc-section\" id=\"The_Commercial_Translation\"><\/span><strong>The Commercial Translation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In simple terms, siRNA tends to win on potency and dosing convenience in the liver, which suits large chronic-disease markets. The most commercially important siRNA applications so far involve liver-expressed targets in amyloid, cardiometabolic and rare metabolic disease. ASOs tend to win on mechanistic flexibility, which suits neurology and rare genetic disease. <\/p>\n\n\n\n<div dir=\"ltr\" align=\"left\">\n<table style=\"border-collapse: collapse; width: 77.6675%; height: 542.167px; border: 1px solid #000000;\" border=\"1\"><colgroup><col style=\"width: 25.8786%;\" width=\"162\"><col style=\"width: 36.901%;\" width=\"231\"><col style=\"width: 37.0607%;\" width=\"232\"><\/colgroup>\n<tbody>\n<tr style=\"height: 67.8542px;\">\n<td style=\"border-width: 1px; border-color: #000000; background-color: #d7e9ff;\">\n<p dir=\"ltr\"><strong>Feature<\/strong><\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #d7e9ff;\">\n<p dir=\"ltr\"><strong>siRNA<\/strong><\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #d7e9ff;\">\n<p dir=\"ltr\"><strong>Antisense (ASO)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 67.8542px;\">\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Structure<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Double-stranded<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Single-stranded<\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 90.25px;\">\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Core mechanism<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">RISC-mediated mRNA cleavage<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">RNase H degradation, splice modulation, steric block<\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 67.8542px;\">\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Main site of action<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Cytoplasm<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Nucleus and cytoplasm<\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 90.25px;\">\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Best-proven delivery<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">GalNAc-conjugate to the liver<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Intrathecal (CNS) and GalNAc-conjugate to the liver<\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 67.8542px;\">\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Typical dosing<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Quarterly to twice yearly<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Monthly to every few months<\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 90.25px;\">\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Commercial sweet spot<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Large chronic indications<\/p>\n<\/td>\n<td style=\"border-width: 1px; border-color: #000000; background-color: #f8f8f8;\">\n<p dir=\"ltr\">Neurology, rare disease, splice correction<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Commercial_Scorecard_What_the_Approved_Drugs_Tell_Us\"><\/span><strong>The Commercial Scorecard: What the Approved Drugs Tell Us<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The commercial performance of approved <a href=\"https:\/\/www.delveinsight.com\/report-store\/rna-therapeutics-market\">RNA therapeutics<\/a> highlights the growing maturity of both siRNA and antisense oligonucleotide platforms, with established products generating billions in annual revenue and newer launches expanding their reach. siRNA drugs are demonstrating blockbuster potential, driven by broader indications, convenient dosing schedules, and entry into large chronic-disease markets. Meanwhile, antisense therapeutics continue to deliver substantial revenues across rare genetic and neuromuscular disorders, supported by established franchises and emerging independent launches. However, intensifying competition, confirmatory trial outcomes, and pricing pressures will shape future growth.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"siRNA_A_Blockbuster_Pipeline_in_the_Making\"><\/span><strong>siRNA: A Blockbuster Pipeline in the Making<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The siRNA therapeutics market is entering a new phase of commercial expansion, with established products demonstrating blockbuster potential and newer launches broadening the platform&#8217;s reach across therapeutic areas. In 2025, marketed siRNA drugs generated approximately <strong>$4.2 billion<\/strong> in disclosed global net sales, led by Alnylam\u2019s AMVUTTRA and Novartis\u2019 LEQVIO.<\/p>\n\n\n\n<p><strong>Alnylam\u2019s AMVUTTRA: The Class Leader<\/strong><\/p>\n\n\n\n<p>The headline story is AMVUTTRA. AMVUTTRA (vutrisiran) is a GalNAc-conjugated small interfering RNA (siRNA) that silences the transthyretin (TTR) gene in the liver, cutting production of both the normal and mutant forms of the protein that misfolds and deposits as amyloid in nerves and the heart. The FDA first approved it in June 2022 for polyneuropathy of hereditary transthyretin-mediated amyloidosis, where it is given as a subcutaneous injection once every three months, a much lighter burden than the intravenous infusions required by its predecessor, <strong>ONPATTRO<\/strong>. In March 2025, the US label expanded to ATTR cardiomyopathy on the strength of the HELIOS-B Phase 3 trial, opening a patient pool far larger than the original rare-disease population.<\/p>\n\n\n\n<p>That expansion is the reason siRNA drugs are now being valued as mass-market products rather than orphan therapies. Alnylam, the siRNA company that pioneered the field and brought the first <a href=\"https:\/\/www.delveinsight.com\/report-store\/rna-interference-therapy-competitive-landscape\">RNAi medicine<\/a> to market with Onpattro in 2018, now has a franchise in which its newest launch is also its biggest. Its two rare-disease products follow the same logic on a smaller scale. <strong>GIVLAARI<\/strong>, approved in 2019, silences the ALAS1 gene to prevent the toxic buildup that triggers acute hepatic porphyria attacks and is dosed monthly. <strong>OXLUMO<\/strong>, approved in 2020, silences the HAO1 gene to lower oxalate production in primary hyperoxaluria type 1, with maintenance doses given quarterly.<\/p>\n\n\n\n<p>After its US approval for ATTR cardiomyopathy, sales more than doubled the TTR franchise, helping Alnylam deliver total 2025 net product revenue of <strong>$2.99 billion<\/strong>, up 81%. Fourth-quarter AMVUTTRA sales alone reached <strong>$827 million<\/strong>. Alnylam&#8217;s own 2026 guidance for the TTR franchise is <strong>$4.4 to $4.7 billion<\/strong>, which would make AMVUTTRA one of the biggest launches in recent pharma history. The rare-disease pair of GIVLAARI and OXLUMO added a steady <strong>$500 million<\/strong>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"323\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/2025-Revenue-of-Approved-siRNA-Drugs-1024x323.webp\" alt=\"2025-Revenue-of-Approved-siRNA-Drugs\" class=\"wp-image-36280\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/2025-Revenue-of-Approved-siRNA-Drugs-1024x323.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/2025-Revenue-of-Approved-siRNA-Drugs-300x95.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/2025-Revenue-of-Approved-siRNA-Drugs-150x47.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/2025-Revenue-of-Approved-siRNA-Drugs-768x242.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/2025-Revenue-of-Approved-siRNA-Drugs-1536x484.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/2025-Revenue-of-Approved-siRNA-Drugs.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><strong>Novartis\u2019 LEQVIO: The Primary-Care Test<\/strong><\/p>\n\n\n\n<p>LEQVIO (inclisiran) is a GalNAc-conjugated siRNA that silences PCSK9 messenger RNA in liver cells. This raises the number of LDL receptors on the cell surface and pulls more LDL cholesterol out of the blood. The molecule was discovered by Alnylam and developed by The Medicines Company, which Novartis acquired in early 2020. It won European approval in December 2020 and FDA approval in December 2021. After an initial dose and a second dose at three months, it is given by a healthcare professional just twice a year, a built-in adherence advantage over daily pills and more frequent injectable PCSK9 antibodies.<\/p>\n\n\n\n<p>LEQVIO reached blockbuster status in 2025, growing 57% to roughly <strong>$1.2 billion<\/strong>. Novartis has said it sees peak sales above <strong>$4 billion<\/strong>, and a pair of cardiovascular outcomes studies are due in 2027. LEQVIO matters beyond its own revenue: it proved that a twice-yearly RNA injection can sell into a mass-market cardiovascular setting.<\/p>\n\n\n\n<p>Momentum has continued into 2026. LEQVIO sales reached <strong>$480 million<\/strong> in the second quarter alone, up 59% at constant currencies, and Novartis has highlighted Medicare Part B, where it held a 23.3% share, as its most important segment. The drug was also added to China&#8217;s National Reimbursement Drug List in late 2025. The main commercial threat is the emerging class of daily <a href=\"https:\/\/www.delveinsight.com\/blog\/impact-of-oral-pcsk9-inhibitors\">oral PCSK9 inhibitors<\/a>, which Novartis management has downplayed, arguing that twice-yearly dosing will keep this siRNA therapeutic competitive.<\/p>\n\n\n\n<p><strong>The New Launches<\/strong><\/p>\n\n\n\n<p><strong>QFITLIA (fitusiran)<\/strong>, discovered by <strong>Alnylam <\/strong>and commercialized by <strong>Sanofi<\/strong>, takes a different route to treating bleeding disorders: instead of replacing a missing clotting factor, it silences antithrombin in the liver to rebalance the clotting system and generate more thrombin. The FDA approved it on March 28, 2025, for routine prophylaxis in people with hemophilia A or B, with or without inhibitors, as a subcutaneous injection on a monthly or bimonthly schedule. <strong>REDEMPLO (plozasiran), Arrowhead&#8217;s <\/strong>first FDA-approved siRNA medicine, silences the APOC3 gene to reduce triglycerides in adults with familial chylomicronemia syndrome and is dosed every three months. It followed approvals in Canada and China, where Sanofi will market it. <strong>RIVFLOZA (nedosiran)<\/strong>, approved in September 2023 and sold by Novo Nordisk, silences the LDHA gene in primary hyperoxaluria type 1 and competes directly with Oxlumo, a reminder that the first siRNA company to reach a market rarely keeps it to itself.<\/p>\n\n\n\n<p>QFITLIA and REDEMPLO are early-stage stories. QFITLIA&#8217;s first-year sales were small, but the product brings siRNA into hemophilia. REDEMPLO launched in the final weeks of 2025, so its commercial story belongs to 2026. By spring 2026, Arrowhead was reporting steady prescription growth and had cut its list price to <strong>$45,000 per year <\/strong>to keep pace with a competitor.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Antisense_The_Pioneer_With_a_Strong_Second_Act\"><\/span><strong>Antisense: The Pioneer With a Strong Second Act<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Antisense is the older of the two RNA platforms, and its commercial history reflects that head start. The first antisense drug, VITRAVENE for cytomegalovirus retinitis, reached the market in 1998, and after a long lull, the field was revived in 2016 by the approvals of <strong>SPINRAZA and EXONDYS 51<\/strong>. Since then, approved antisense oligonucleotides have built a base of roughly <strong>$3 billion<\/strong> in annual sales, concentrated in neuromuscular and rare genetic disease. The antisense oligonucleotides market is now entering a second phase, in which new launches from Ionis and its partners are widening the range of antisense oligonucleotides drugs beyond ultra-rare indications.&nbsp;<\/p>\n\n\n\n<p><strong>Biogen\/Ionis SPINRAZA: Still the Anchor, But Flat<\/strong><\/p>\n\n\n\n<p>SPINRAZA (nusinersen) is an ASO that corrects the splicing of the SMN2 gene so the body makes more functional SMN protein, the shortage of which causes spinal muscular atrophy. Discovered by Ionis and commercialized by Biogen, it was approved by the FDA in December 2016 as the first treatment for the disease and has since been cleared in dozens of countries. It is delivered directly into the spinal fluid by lumbar puncture, with a loading phase followed by maintenance doses every four months. Its growth has stalled because newer rivals, including the <strong>ZOLGENSMA <\/strong>gene therapy and the oral drug <strong>EVRYSDI<\/strong>, now compete for the same patients. The higher-dose regimen, first approved in Japan, is Biogen&#8217;s main answer.<\/p>\n\n\n\n<p>SPINRAZA remains the largest antisense product by sales, yet it is a plateauing one. Revenue was essentially unchanged from 2024, and Biogen expects roughly flat sales in 2026 as it works to defend the franchise with a higher-dose regimen. In addition to Biogen&#8217;s sales, Ionis collected about <strong>$212 million<\/strong> in SPINRAZA royalties in 2025.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"323\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/2025-Revenue-of-Approved-Antisense-Drugs-1024x323.webp\" alt=\"2025-Revenue-of-Approved-Antisense-Drugs\" class=\"wp-image-36281\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/2025-Revenue-of-Approved-Antisense-Drugs-1024x323.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/2025-Revenue-of-Approved-Antisense-Drugs-300x95.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/2025-Revenue-of-Approved-Antisense-Drugs-150x47.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/2025-Revenue-of-Approved-Antisense-Drugs-768x242.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/2025-Revenue-of-Approved-Antisense-Drugs-1536x484.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/2025-Revenue-of-Approved-Antisense-Drugs.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><strong>The Exon-Skipping Franchise<\/strong><\/p>\n\n\n\n<p>Sarepta&#8217;s three exon-skippers generated <strong>$966 million<\/strong>. The fourth-quarter split showed Exondys 51 at <strong>$148 million<\/strong>, Amondys 45 at <strong>$77 million<\/strong>, and Vyondys 53 at <strong>$34 million<\/strong>. This is a durable, rare-disease cash stream, though Sarepta&#8217;s wider fortunes have been shaped by its <a href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-duchenne-muscular-dystrophy\">DMD gene therapy<\/a> rather than by these drugs.<\/p>\n\n\n\n<p>All three drugs are phosphorodiamidate morpholino oligomers that skip a specific exon of the dystrophin gene, restoring the reading frame so the body can make a shortened but partly functional dystrophin protein. Exondys 51 (eteplirsen), approved in September 2016, targets exon 51 and suits roughly 13% of Duchenne patients. Vyondys 53 (golodirsen), approved in December 2019, targets exon 53, and Amondys 45 (casimersen), approved in February 2021, targets exon 45; each suits about 8% of patients. A fourth exon-skipper, <strong>VILTEPSO (viltolarsen)<\/strong> from <strong>Nippon Shinyaku<\/strong>, was approved in 2020 and also targets exon 53. All of these received accelerated approval based on dystrophin production, which makes confirmatory evidence a live issue: the ESSENCE trial of Amondys 45 and Vyondys 53 missed its primary endpoint in November 2025, and Sarepta is now discussing a path to traditional approval with the FDA.<\/p>\n\n\n\n<p><strong>Ionis&#8217;s Independent Launches<\/strong><\/p>\n\n\n\n<p>For Ionis, 2025 was the year it became a commercial company. <strong>TRYNGOLZA <\/strong>reached <strong>$108 million <\/strong>in its first year, with <strong>$50 million<\/strong> in the fourth quarter alone, and <strong>DAWNZERA <\/strong>opened with a modest first partial year. Ionis also earned about <strong>$49 million<\/strong> in royalties on <strong>WAINUA<\/strong>. TRYNGOLZA (olezarsen) is a GalNAc-conjugated ASO that silences the APOC3 gene to lower triglycerides. The FDA approved it in December 2024 for familial chylomicronemia syndrome as a once-monthly injection, making it the first drug Ionis launched on its own.&nbsp;<\/p>\n\n\n\n<p>DAWNZERA (donidalorsen) targets prekallikrein, the protein that drives swelling attacks in hereditary angioedema, and was approved on August 21, 2025, for prophylaxis in patients aged 12 and older, with self-administered dosing every four or eight weeks. Two earlier Ionis-discovered medicines sit with partners. <a href=\"https:\/\/www.delveinsight.com\/blog\/wainua-for-hattr-pn-treatment\">WAINUA (eplontersen)<\/a>, co-developed with AstraZeneca and approved in December 2023 for hereditary transthyretin polyneuropathy, is a monthly autoinjector that competes head-on with Alnylam&#8217;s AMVUTTRA. <strong>QALSODY (tofersen)<\/strong>, approved in April 2023 and sold by Biogen, is the first treatment aimed at the genetic cause of SOD1-related ALS and is given into the spinal fluid.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_RNA_Drug_Pipeline_in_2026_Blockbuster_Potential_and_Clinical_Setbacks\"><\/span><strong>The RNA Drug Pipeline in 2026: Blockbuster Potential and Clinical Setbacks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The RNA therapeutics landscape is entering a pivotal phase in 2026, as emerging siRNA and antisense oligonucleotide drugs advance toward broader patient populations and major commercial opportunities. Late-stage clinical trials are increasingly testing whether these therapies can deliver meaningful clinical benefits beyond improvements in biomarkers. While several programs are approaching regulatory milestones and potential blockbuster status, recent trial setbacks have raised questions about established treatment hypotheses and market expectations. Together, these developments are reshaping the competitive landscape and future growth prospects for RNA-based therapeutics.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Emerging_siRNA_Drugs_The_Next_Wave_Aims_at_Mass_Markets\"><\/span><strong>Emerging siRNA Drugs: The Next Wave Aims at Mass Markets<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The siRNA pipeline is where the class&#8217;s biggest ambitions sit. Several late-stage programs target conditions that affect tens of millions of people, and the siRNA therapeutics now in Phase 3 are increasingly judged on cardiovascular outcomes rather than biomarker changes.<\/p>\n\n\n\n<p>The most ambitious program is <strong>zilebesiran<\/strong>, a twice-yearly angiotensinogen silencer being co-developed by Alnylam and Roche for hypertension. It is now in the <strong>ZENITH Phase <\/strong>3 cardiovascular outcomes trial, which plans to enroll around 11,000 patients with uncontrolled hypertension, and starting the trial triggered a <strong>$300 million<\/strong> milestone payment from Roche. Hypertension is arguably the largest chronic-disease market any RNA drug has attempted. Alongside it, <strong>plozasiran <\/strong>from Arrowhead, already approved as <a href=\"https:\/\/www.delveinsight.com\/blog\/redemplo-for-fcs\">REDEMPLO for familial chylomicronemia syndrome<\/a>, posted positive <strong>Phase 3 SHASTA-3 and SHASTA-4 results<\/strong> in severe hypertriglyceridemia in July 2026. Median triglycerides fell about 79% to 81% versus roughly 27% on placebo, and acute pancreatitis events were reduced by 78% in the broad population. Arrowhead plans a US filing by the end of 2026, and consensus forecasts compiled by S&amp;P Global earlier pointed to potential peak global sales above <strong>$2 billion<\/strong>.<\/p>\n\n\n\n<p>A second cluster of programs is racing to lower lipoprotein(a), a genetically determined cardiovascular risk factor. <strong>Amgen&#8217;s olpasiran<\/strong> is being tested in the OCEAN(a)-Outcomes trial of about 7,300 patients, one of the most closely watched cardiovascular readouts in the industry, with ClinicalTrials.gov currently listing primary completion in 2028. <strong>Eli Lilly&#8217;s lepodisiran<\/strong> is in the ACCLAIM-Lp(a) outcomes trial, which tests dosing as infrequent as every six months, and <strong>Silence Therapeutics&#8217; zerlasiran<\/strong> has reported Lp(a) reductions of about 96% in clinical studies. These programs now carry more scientific risk than they did a month ago. In September 2026, the first Lp(a) outcomes trial, of the antisense drug pelacarsen, failed to reduce cardiovascular events despite lowering Lp(a). That result does not prove the siRNA programs will fail, since they use different molecules and trial designs, but it raises a legitimate question about the Lp(a) hypothesis itself.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"377\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-siRNA-Drugs-Under-Development-1024x377.webp\" alt=\"Comparison-of-Emerging-siRNA-Drugs-Under-Development\" class=\"wp-image-36282\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-siRNA-Drugs-Under-Development-1024x377.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-siRNA-Drugs-Under-Development-300x110.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-siRNA-Drugs-Under-Development-150x55.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-siRNA-Drugs-Under-Development-768x282.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-siRNA-Drugs-Under-Development-1536x565.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-siRNA-Drugs-Under-Development.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Alnylam is also building the successor to its own best-seller. <strong>Nucresiran<\/strong>, a next-generation TTR silencer dosed every six months, is in Phase 3 in both cardiomyopathy (TRITON-CM) and polyneuropathy (TRITON-PN). Alnylam expanded TRITON-CM enrollment to about 1,750 patients in April 2026 after faster-than-expected recruitment, and approval in cardiomyopathy is targeted around 2030. Beyond cardiometabolic disease, <strong>cemdisiran<\/strong>, a complement C5 silencer partnered with Regeneron, has a regulatory submission planned for 2026. Earlier-stage programs extend siRNA applications into new territory: mivelsiran is being tested in cerebral amyloid angiopathy and Alzheimer&#8217;s disease, and <strong>ALN-6400<\/strong> in bleeding disorders, pushing RNAi into the brain and into hematology.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Emerging_Antisense_Drugs_Big_Wins_and_Big_Setbacks_in_2026\"><\/span><strong>Emerging Antisense Drugs: Big Wins and Big Setbacks in 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The antisense pipeline has had a dramatic year, with both good and bad news, and the results of several antisense oligonucleotides clinical trials have redrawn expectations for the class. The biggest win is <a href=\"https:\/\/www.delveinsight.com\/blog\/tryngolza-approval-for-severe-hypertriglyceridemia\">olezarsen (TRYNGOLZA) in severe hypertriglyceridemia<\/a>. The FDA approved the label expansion in late June 2026, taking TRYNGOLZA from an ultra-rare disease to a large patient population. Ionis has raised its peak-sales guidance to more than <strong>$2 billion<\/strong> and lowered the list price to <strong>$40,000 a year<\/strong>, making it the single most important commercial catalyst for the antisense oligonucleotides market.<\/p>\n\n\n\n<p>The pipeline is also delivering in neurology and infectious disease. <strong>Zilganersen (ZANVASTRO)<\/strong>, approved by the FDA on September 3, 2026, is the first disease-modifying treatment for Alexander disease and Ionis&#8217;s first independent launch from its neurology pipeline. <strong>Bepirovirsen<\/strong>, partnered with GSK for chronic hepatitis B, reported positive pivotal Phase 3 results in early 2026. Because hepatitis B affects hundreds of millions of people worldwide, it is potentially the largest-volume antisense opportunity in development. Earlier assets add depth: <strong>ION582 <\/strong>is in a Phase 3 program for Angelman syndrome, a severe neurodevelopmental disorder, and <strong>ION775 <\/strong>has entered a Phase 2 study in people with severe hypertriglyceridemia, while Ionis reports multiple neurology readouts due in 2026.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"364\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-Antisense-Drugs-Under-Development-1024x364.webp\" alt=\"Comparison-of-Emerging-Antisense-Drugs-Under-Development\" class=\"wp-image-36283\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-Antisense-Drugs-Under-Development-1024x364.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-Antisense-Drugs-Under-Development-300x107.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-Antisense-Drugs-Under-Development-150x53.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-Antisense-Drugs-Under-Development-768x273.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-Antisense-Drugs-Under-Development-1536x546.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-Antisense-Drugs-Under-Development.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The setbacks were just as notable. On September 4, 2026, the Lp(a)HORIZON trial of <strong>pelacarsen <\/strong>(Novartis\/Ionis) in about 8,300 patients missed its primary cardiovascular endpoint even though the drug lowered Lp(a), a blow to the highest-profile antisense program in cardiology. Weeks earlier, the CARDIO-TTRansform trial of eplontersen (WAINUA) in 1,432 patients with ATTR cardiomyopathy, presented at the ESC Congress in August 2026, showed no significant benefit in the overall population: 381 primary events with eplontersen against 392 with placebo. A subgroup not using stabilizers showed a nominal benefit, but the main result removes the cardiomyopathy expansion that analysts had priced in, and AstraZeneca shares fell sharply on the news.<\/p>\n\n\n\n<p>The <strong>eplontersen <\/strong>result is especially striking because it sits next to siRNA&#8217;s success in the same disease. Alnylam&#8217;s AMVUTTRA won an ATTR-CM approval and is now the engine of its growth.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Commercial_Verdict_Who_Has_the_Greater_Potential\"><\/span><strong>The Commercial Verdict: Who Has the Greater Potential?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>siRNA currently holds an advantage over antisense oligonucleotides (ASOs) in several key areas, including revenue generation, dosing convenience, clinical validation, and late-stage pipeline breadth. siRNA generates approximately 40% more disclosed revenue than antisense, while its leading product continues to deliver triple-digit growth. Its dosing durability, with administration schedules ranging from quarterly to twice yearly, can improve treatment adherence and support premium pricing in chronic diseases. The success of LEQVIO has also demonstrated that RNA interference therapies can gain traction in primary-care cardiovascular medicine. Furthermore, <a href=\"https:\/\/www.delveinsight.com\/blog\/small-interfering-rna-sirna-therapeutics-competitive-landscape-technology-and-pipeline-insights-2015-a-delveinsights-report\">siRNA therapeutics<\/a> have delivered a positive result in a major cardiovascular outcomes setting in ATTR-CM, while antisense therapies have recently fallen short in two such trials. Its late-stage pipeline also offers considerable growth potential, with zilebesiran, nucresiran, and plozasiran targeting indications that encompass very large patient populations.<\/p>\n\n\n\n<p>Despite these advantages, antisense technology remains highly relevant and retains several distinct strengths. ASOs continue to lead in neurology, as no siRNA therapy has yet matched their ability to reach the central nervous system (CNS), and newer approvals, such as ZANVASTRO, further reinforce this position. Their broader mechanistic versatility, including splice modulation and nuclear targeting, also provides advantages that siRNA does not currently replicate. In addition, TRYNGOLZA, which is already approved for severe hypertriglyceridemia, represents a substantial near-term commercial opportunity and could potentially exceed $2 billion in sales on its own. Antisense therapies also retain significant potential in infectious diseases, particularly hepatitis B, where the potential market entry of bepirovirsen could open a new chapter for the technology.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/antisense-therapies-market-forecast\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Antisense-Therapies-Market-Outlook-1024x194.webp\" alt=\"Antisense Therapies Market Outlook\" class=\"wp-image-36277\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Antisense-Therapies-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Antisense-Therapies-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Antisense-Therapies-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Antisense-Therapies-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Antisense-Therapies-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Antisense-Therapies-Market-Outlook.webp 1584w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary A little over a decade ago, silencing a disease gene with a few injections a year sounded like science fiction. Today it is a multi-billion-dollar business. Oligonucleotide drugs now sit among the fastest-growing classes in pharma, and two technologies lead the field: small interfering RNA (siRNA) and antisense oligonucleotides (ASOs). Both switch off disease [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":36278,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[23153,2025,18973,23066,22502,22776,23152,23137,537,23154,23151,2357,22778,21626,4221],"industry":[17225],"therapeutic_areas":[17235],"class_list":["post-36275","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-amvuttra","tag-antisense-oligonucleotides-asos","tag-leqvio","tag-oral-pcsk9-inhibitors","tag-qfitlia","tag-redemplo","tag-rna-technology","tag-rna-therapeutic","tag-sirna","tag-sirna-therapeutics","tag-sirna-vs-asos","tag-spinraza","tag-tryngolza","tag-wainua","tag-zolgensma","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>siRNA vs. ASOs: Which RNA Technology Will Win the Market?<\/title>\n<meta name=\"description\" content=\"siRNA and antisense oligonucleotides are leading RNA-based therapies that target disease by modulating gene expression.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"siRNA vs. ASOs: Which RNA Technology Will Win the Market?\" \/>\n<meta property=\"og:description\" content=\"siRNA and antisense oligonucleotides are leading RNA-based therapies that target disease by modulating gene expression.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-16T12:11:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/sirna-vs-antisense-oligonucleotides.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"17 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"siRNA vs. ASOs: Which RNA Technology Will Win the Market?","description":"siRNA and antisense oligonucleotides are leading RNA-based therapies that target disease by modulating gene expression.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides","og_locale":"en_US","og_type":"article","og_title":"siRNA vs. ASOs: Which RNA Technology Will Win the Market?","og_description":"siRNA and antisense oligonucleotides are leading RNA-based therapies that target disease by modulating gene expression.","og_url":"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-10-16T12:11:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/sirna-vs-antisense-oligonucleotides.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"siRNA vs. Antisense Oligonucleotides: Which RNA Technology Has Greater Commercial Potential?","datePublished":"2026-10-16T12:11:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides"},"wordCount":3368,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/sirna-vs-antisense-oligonucleotides.webp","keywords":["AMVUTTRA","antisense oligonucleotides (ASOs","Leqvio","Oral PCSK9 Inhibitors","Qfitlia","REDEMPLO","RNA Technology","RNA Therapeutic","siRNA","siRNA Therapeutics","siRNA vs. ASOs","Spinraza","TRYNGOLZA","Wainua","Zolgensma"],"articleSection":["Articles"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides","url":"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides","name":"siRNA vs. ASOs: Which RNA Technology Will Win the Market?","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/sirna-vs-antisense-oligonucleotides.webp","datePublished":"2026-10-16T12:11:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"siRNA and antisense oligonucleotides are leading RNA-based therapies that target disease by modulating gene expression.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/sirna-vs-antisense-oligonucleotides#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/sirna-vs-antisense-oligonucleotides.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/sirna-vs-antisense-oligonucleotides.webp","width":466,"height":284,"caption":"sirna-vs-antisense-oligonucleotides"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/sirna-vs-antisense-oligonucleotides-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AMVUTTRA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">antisense oligonucleotides (ASOs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Leqvio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oral PCSK9 Inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Qfitlia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">REDEMPLO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">RNA Technology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">RNA Therapeutic<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">siRNA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">siRNA Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">siRNA vs. ASOs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Spinraza<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TRYNGOLZA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wainua<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Zolgensma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AMVUTTRA<\/span>","<span class=\"advgb-post-tax-term\">antisense oligonucleotides (ASOs<\/span>","<span class=\"advgb-post-tax-term\">Leqvio<\/span>","<span class=\"advgb-post-tax-term\">Oral PCSK9 Inhibitors<\/span>","<span class=\"advgb-post-tax-term\">Qfitlia<\/span>","<span class=\"advgb-post-tax-term\">REDEMPLO<\/span>","<span class=\"advgb-post-tax-term\">RNA Technology<\/span>","<span class=\"advgb-post-tax-term\">RNA Therapeutic<\/span>","<span class=\"advgb-post-tax-term\">siRNA<\/span>","<span class=\"advgb-post-tax-term\">siRNA Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">siRNA vs. ASOs<\/span>","<span class=\"advgb-post-tax-term\">Spinraza<\/span>","<span class=\"advgb-post-tax-term\">TRYNGOLZA<\/span>","<span class=\"advgb-post-tax-term\">Wainua<\/span>","<span class=\"advgb-post-tax-term\">Zolgensma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 minutes ago","modified":"Updated 4 days ago"},"absolute_dates":{"created":"Posted on Oct 16, 2026","modified":"Updated on Oct 12, 2026"},"absolute_dates_time":{"created":"Posted on Oct 16, 2026 5:41 pm","modified":"Updated on Oct 12, 2026 3:42 pm"},"featured_img_caption":"sirna-vs-antisense-oligonucleotides","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=36275"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36275\/revisions"}],"predecessor-version":[{"id":36284,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36275\/revisions\/36284"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/36278"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=36275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=36275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=36275"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=36275"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=36275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}